Everolimus in de Novo Kidney Transplant Recipients
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate whether delayed (i.e. 28 ± 4 days post-transplant)
administration of everolimus after transplantation reduces the risk of wound healing
complications in comparison with immediate administration in de novo renal transplant
patients (proportion of patients without wound/surgical complications related to initial
transplant surgery) between randomization and 3 months after transplantation.